Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07602127Early Phase 1Not Yet Recruiting

Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy

Role: lead

NCT07282457Phase 1Not Yet Recruiting

Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

Role: lead

NCT06292650Early Phase 1Recruiting

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Role: lead

NCT06066008Early Phase 1Completed

Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

Role: lead

NCT07085533Recruiting

Natural History Study of Inherited Retinal Diseases

Role: lead

All 5 trials loaded